scholarly journals Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

Oncotarget ◽  
2015 ◽  
Vol 6 (26) ◽  
pp. 22496-22512 ◽  
Author(s):  
David M. Goldenberg ◽  
Thomas M. Cardillo ◽  
Serengulam V. Govindan ◽  
Edmund A. Rossi ◽  
Robert M. Sharkey
Keyword(s):  
Cancer Therapy ◽  
Solid Cancer ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Novel Target ◽  
Antibody Drug

scholarly journals Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

Oncotarget ◽  
2020 ◽  
Vol 11 (10) ◽  
pp. 942-942
Author(s):  
David M. Goldenberg ◽  
Thomas M. Cardillo ◽  
Serengulam V. Govindan ◽  
Edmund A. Rossi ◽  
Robert M. Sharkey
Keyword(s):  
Cancer Therapy ◽  
Solid Cancer ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Novel Target ◽  
Antibody Drug

Abstract 42: Preclinical development of a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer

2017 ◽  
Author(s):  
Thomas Son ◽  
Juniper A. Scribner ◽  
Jeff Hooley ◽  
Michael Chiechi ◽  
Pam Li ◽  
...  
Keyword(s):  
Solid Cancer ◽  
Antibody Drug Conjugate ◽  
Preclinical Development ◽  
Drug Conjugate ◽  
Antibody Drug

Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy

2019 ◽  
Vol 235 (1) ◽  
pp. 31-64 ◽  
Author(s):  
Sajad Yaghoubi ◽  
Mohammad Hossein Karimi ◽  
Majid Lotfinia ◽  
Tohid Gharibi ◽  
Motahare Mahi‐Birjand ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug

TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma

2020 ◽  
pp. 106689692097859
Author(s):  
Jae Yeon Seok ◽  
Kristine Astvatsaturyan ◽  
Mariza De Peralta-Venturina ◽  
Jinping Lai ◽  
Xuemo Fan
Keyword(s):  
Thyroid Carcinoma ◽  
De Novo ◽  
Anaplastic Thyroid Carcinoma ◽  
Antibody Drug Conjugate ◽  
Isocitrate Dehydrogenase 1 ◽  
Entire Cohort ◽  
Drug Conjugate ◽  
Idh1 R132h ◽  
Novel Target ◽  
Antibody Drug

Background Anaplastic thyroid carcinoma (ATC), a highly aggressive malignancy, has no effective treatment to date. Trophoblast cell-surface antigen 2 (TROP-2), a transmembrane glycoprotein, has been suggested to be a promising novel target for sacituzumab govitecan, an antibody-drug conjugate. 5-Hydroxymethylcytosine (5hmC) has a role in tumor suppression and promoting modification. Additionally, isocitrate dehydrogenase 1 (IDH1) mutations are strongly associated with increased overall survival in gliomas and worse prognosis in leukemias. This study attempts to evaluate the immunoexpression of TROP-2, 5hmC, and IDH1 in ATCs and to determine their potential impact in targeted therapy. Methods Twenty-four ATCs were retrieved, with 9 cases that occurred de novo and 15 cases derived from either papillary thyroid carcinoma (PTC) or follicular thyroid carcinoma (FTC). Sections were immunostained with TROP-2, 5hmC, and IDH1 antibodies, and evaluated using the QuPath program. The t tests were performed using SPSS software. Results TROP-2 was detected in 12 ATCs with 9 cases demonstrating a high expression and in all PTC components, and absent in all FTC components of secondary ATCs. 5hmC expression was moderately reduced in PTC and FTC components and markedly reduced in ATC. The entire cohort showed a total absence of IDH1. Conclusions Increased TROP-2 immunoexpression in some ATCs supports that these patients may potentially benefit from an antibody-drug conjugate therapy targeting TROP-2. Markedly reduced 5hmC expression suggests that 5hmC may be used as potential therapeutic targets for ATC. The total lack of IDH1 R132H mutation by immunostain indicates that it has no prognostic and therapeutic value in ATC.

Sign in / Sign up

Export Citation Format

Share Document